DS: Lower Respiratory Infection Flashcards by Sandrea Dumadag | Brainscape

Q

Empiric Treatment for
Outpatient - CAP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

CAP Pathogens

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Empiric Treatment for
Outpatient - CAP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Empiric Treatment for Adult Inpatient - Non severe CAP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Empiric Treatment for Adult Inpatient - Severe CAP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Considerations for Treating Adult CAP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Newer Antibiotic for CAP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Directed Therapy of CAP in Adult Patients

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Influenza Treatment

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Empiric treatment for pediatrics - Outpatient setting CAP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Empiric treatment for pediatrics - Inpatient setting CAP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Directed therapy for CAP in Pediatric patients

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Influenza Vaccination

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Pediatrics CAP common pathogen

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HAP & VAP
Common Pathogen

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Consideration in Selecting Empiric Therapy for HAP

A

Q

Empiric HAP Therapy
Low mortality and MDR risk

A

Q

Consideration in choosing empiric for VAP treatment

A

Q

Empiric VAP Therapy
No MDR Risk and GNR resistance is <10%

A

Q

Empiric VAP Therapy
No MDR Risk and GNR resistance is >10%

A

Q

Empiric VAP Therapy
MDR VAP Risk Factors

A

Q

A

Q

HAP and VAP - Pathogen Specific
MRSA and PsA

A

Q

A

Q

HAP and VAP Pathogen Specifici
ESBL and AMPc Producing Enterobacterales

A

Q

HAP and VAP Pathogen specific
CRE

A

Q

Hap and Vap Pathogen Specific
Acinetobacter sp.

A

Q

HAP and VAP Pathogen specific
Stenotrophomonas Maltophila

A

Q

Newer Abx for HAP & VAP

A

Q

Newer Abx for HAP/VAP

A

Q

Duration of Abx Therapy
HAP & VAP

A

Q

ZEPHyR Study

A

Vancomycin vs. Linezolid
-Linezolid group has greater clinical response, and 60-day mortality
-Tx guidelines consider the two drugs for be comparable efficacy despite higher clinical and micro success with linezolid due to study limitation

Q

Merino Trial

A

Zosyn vs. Merrem on CTX resistant E.coli and K.pnuemo
- Shows that zosyn may not be equivalent to merrem for serious ESBL infections